Serge Belanger, an analyst from Needham, maintained the Buy rating on Liquidia Technologies (LQDA – Research Report). The associated price target remains the same with $25.00.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Serge Belanger has given his Buy rating due to a combination of factors surrounding Liquidia Technologies’ current legal situation and market potential. Despite a new lawsuit filed by United Therapeutics (UTHR) against Liquidia, alleging patent infringement related to Yutrepia, Belanger believes this legal action is unlikely to affect the near-term FDA approval of Yutrepia’s New Drug Application (NDA), expected by May 24, 2025.
The lawsuit seems to be a strategic move by UTHR to delay Liquidia’s market entry rather than a strong legal challenge, as the patent in question is part of the same family as a previously invalidated patent. The previous invalidation was upheld by higher courts, suggesting a weak basis for UTHR’s current claims. Consequently, Belanger views the lawsuit as unlikely to succeed in preventing Yutrepia’s commercial launch, reinforcing his positive outlook on Liquidia’s stock.
Belanger covers the Healthcare sector, focusing on stocks such as Liquidia Technologies, Cytokinetics, and Esperion. According to TipRanks, Belanger has an average return of -0.3% and a 38.86% success rate on recommended stocks.
In another report released today, H.C. Wainwright also maintained a Buy rating on the stock with a $29.00 price target.